Spatio-temporal analysis of Texas shoreline changes using GIS technique

One of the most important aspects of coastal management and planning programs that needs to be investigated is shoreline dynamics. Long-term coastal analysis uses historical data to identify the sectors along the coast where the shoreline position has changed. Among the information that can be obtained from these studies are the general trend of coasts, either advancing or retreating. The erosion or accretion rates at each location can be used to forecast future shoreline positions. The current techniques used to study shoreline evolution are generally based on transects perpendicular to a baseline at selected points. But these techniques proved to be less efficient along more complex shorelines, and need to be refined. A new and more reliable method, the topologically constrained transect method (TCTM), was developed for this study and tested using data available for three sectors of the Texas Gulf Coast. Output data generated from TCTM also allowed performing shoreline evolution analysis and forecasting based on historical positions. Using topological constrained transects, this study provides a new method to estimate total areas of accretion or erosion at each segment of the coastline. Reliable estimates of future gains or losses of land along the coast will be extremely useful for planning and management decisions, especially those related to infrastructure and environmental impacts, and in the development of coastal models. Especially important is the potential to quickly identify areas of significant change, which eliminates the need for preliminary random sample surveying, and concentrate higher-resolution analyses in the most significant places. The results obtained in this research using the new methodology show that the Texas coast generally experiences erosion, with anthropogenic factors responsible for accretion. Accretion areas are located near coastal infrastructure, especially jetties that block the along shore sediment transport. The maximum erosion rate obtained in the study area is 5.48 m/year. This value helps make us aware of the powerful dynamic of the sector

Inteligencia emocional y desempeño laboral en los trabajadores de la Sub Región de Salud de Sullana - 2019

Esta investigación tiene como objetivo determinar la relación entre la Inteligencia Emocional y el Desempeño Laboral de los trabajadores de la Sub Región de Salud de Sullana. Asimismo presenta un tipo de estudio aplicado, ya que está orientada a la resolución de problemas, el nivel de la investigación es correlacional ya que determina la relación entre ambas variables de estudios a través de un diseño no experimental. Asimismo las técnicas de recolección de datos que se emplearon fueron la encuesta dirigida a trabajadores de la Sub Región de Salud de Sullana y una entrevista al director de recursos humanos de esta entidad, cuya población estuvo integrada por 180 trabajadores y como muestra se optó escoger a toda la población dado el pequeño tamaño de la población. Finalmente, se concluyó que si existe una relación entre la Inteligencia Emocional y el Desempeño Laboral en los trabajadores de la Sub Región de Salud de Sullana, dado que el nivel de significancia es p<.05 y el coeficiente de correlación de Rho de Spearman representa ,396 lo que significa una correlación significativa, por lo tanto a medida que se logre fortalecer la inteligencia emocional de los trabajadores el desempeño laboral de estos mejorará rotundamente

Determinación de la elasticidad de la demanda alimenticia en Ecuador / Determining the elasticity of demand for food in Ecuador

Este trabajo presenta los resultados de un proyecto de investigación financiado por Sistema de Investigación y Desarrollo de la Universidad Católica de Santiago de Guayaquil (SINDE-UCSG), tiene como objetivo determinar la elasticidad de la demanda de alimentos en el Ecuador mediante el uso de técnicas estimativas, para poder generar una herramienta eficaz para el diseño de políticas públicas. Además determinar las posibles razones por las que puede variar la demanda de alimentos en el Ecuador, principalmente por la influencia del factor precio. La realidad social existente sugiere la cuantificación del comportamiento de los ecuatorianos ante el consumo de alimentos, con el objetivo de generar un insumo para la toma de decisiones a nivel de políticas públicas. AbstractThis paper presents the results of a research project funded by System of Research and Development of the Catholic University of Santiago de Guayaquil (SINDE - UCSG). It aims to determine the elasticity of demand for food in Ecuador using predictive techniques, to create an effective public policy design tool. A second aim is to identify possible reasons that can vary the demand for food in Ecuador, mainly through the influence of the price factor. The existing social reality suggests quantifying the behavior of Ecuadorians with regard to the consumption of food, in order to generate a source of information for decision-making at policy level

Improved measurement for mothers, newborns and children in the era of the Sustainable Development Goals.

BACKGROUND: An urgent priority in maternal, newborn and child health is to accelerate the scale-up of cost-effective essential interventions, especially during labor, the immediate postnatal period and for the treatment of serious infectious diseases and acute malnutrition.  Tracking intervention coverage is a key activity to support scale-up and in this paper we examine priorities in coverage measurement, distinguishing between essential interventions that can be measured now and those that require methodological development. METHODS: We conceptualized a typology of indicators related to intervention coverage that distinguishes access to care from receipt of an intervention by the population in need.  We then built on documented evidence on coverage measurement to determine the status of indicators for essential interventions and to identify areas for development. RESULTS: Contact indicators from pregnancy to childhood were identified as current indicators for immediate use, but indicators reflecting the quality of care provided during these contacts need development. At each contact point, some essential interventions can be measured now, but the need for development of indicators predominates around interventions at the time of birth and interventions to treat infections. Addressing this need requires improvements in routine facility based data capture, methods for linking provider and community-based data, and improved guidance for effective coverage measurement that reflects the provision of high-quality care. CONCLUSION: Coverage indicators for some essential interventions can be measured accurately through household surveys and be used to track progress in maternal, newborn and child health.  Other essential interventions currently rely on contact indicators as proxies for coverage but urgent attention is needed to identify new measurement approaches that directly and reliably measure their effective coverage

Research Ethics Training in Peru: A Case Study

With the rapidly increasing number of health care professionals seeking international research experience, comes an urgent need for enhanced capacity of host country institutional review boards (IRB) to review research proposals and ensure research activities are both ethical and relevant to the host country customs and needs. A successful combination of distance learning, interactive courses and expert course instructors has been applied in Peru since 2004 through collaborations between the U.S. Naval Medical Research Center Detachment, the University of Washington and the Department of Clinical Bioethics of the National Institutes of Health to provide training in ethical conduct of research to IRB members and researchers from Peru and other Latin American countries. All training activities were conducted under the auspices of the Peruvian National Institute of Health (INS), Ministry of Health. To date, 927 people from 12 different Latin American countries have participated in several of these training activities. In this article we describe our training model

Study of Thermal Properties on the Different Layers Composing a Commercial Ceramic Tile

In this study the thermal conductivity of a commercial ceramic is determined considering that this property is an essential factor on the building materials. This is the primary indicator of the material suitableness for energy transfer, considering that this kind of construction supplies has many applications as thermal insulations. In this sense, we consider that a commercial tile is usually composed of three layers: substrate, a so-called engine layer, and an enamel layer. Likewise, the thermal properties of the different layers were obtained individually by using two photothermal techniques on the ceramic material; the ceramic tile density was obtained using the Archimedes method. The calculated values show a wide range of thermal conductivity values for the different layers, ranging from1.3 to 4 W m¡1K¡1

Exercício em pacientes oncológicos: reabilitação

Este estudo revisou artigos nas bases de dados do MEDLINE (Pub-Med) e outras fontes de pesquisa, sem limite de tempo. Para tanto, adotou-se a estratégia de busca baseada em perguntas estruturadas na forma (P.I.C.O.) das iniciais: "Paciente"; "Intervençao"; "Controle" e "Outcome". Como descritores utilizaram-se:(Neoplasms OR Carcinogens OR Tumors OR Cancer) AND (Fatigue OR Asthenia OR Lassitude OR Muscle Fatigue OR Fatigue OR Muscles OR specific muscle OR Mental Fatigue OR Fatigue, Mental OR Cancer-related fatigue) AND (Exercise OR Physical Fitness OR Exertion OR Exercise Therapy OR Sports OR Exercise Movement Techniques OR Physical Fitness OR Physical Conditioning OR Physical Endurance); (Neoplasms OR Carcinogens OR Tumors OR Cancer) AND (Fatigue OR Asthenia OR Lassitude OR Muscle Fatigue OR Fatigue OR Muscles OR Specific Muscle OR Mental Fatigue OR Fatigue, Mental OR Cancer-related Fatigue) AND (Chemotherapy, Adjuvant OR Combined Modality Therapy OR Drug Therapy,combination OR Antineoplastic Combined Chemotherapy Protocols) AND (Exercise Tolerance OR Oxigen Consumption*&nbsp;OR Exercise OR Physical Fitness OR Exertion OR Exercise Therapy OR Sports OR Physical Fitness OR Physical Conditioning OR Physical Endurance); (Neoplasms OR Carcinogens OR Tumors OR Cancer) AND (Fatigue OR Asthenia OR Lassitude OR Muscle Fatigue OR Fatigue OR Muscles OR specific muscle OR Mental Fatigue OR Fatigue, Mental OR cancer-related fatigue) AND (Exercise OR Physical Fitness OR Exertion OR Exercise Therapy OR Sports OR Exercise Movement Techniques OR Physical Fitness OR Physical Conditioning OR Physical Endurance OR Intensity exercise); (Neoplasms OR Carcinogens OR Tumors OR Cancer) AND (Fatigue OR Asthenia OR Lassitude OR Muscle Fatigue OR Cancer-related fatigue) AND (Exercise OR Physical Fitness OR Exertion OR Exercise Therapy OR Sports OR Sports OR Exercise Movement Techniques OR Physical Fitness OR Physical Conditioning OR Physical Endurance); Neoplasm AND (Exercise OR Physical Fitness OR Exertion OR Exercise Therapy OR Sports OR Exercise Movement Techniques OR Physical Fitness OR Physical Conditioning OR Physical Endurance) AND Quality of Life ; (Bone Neoplasms OR Neoplasms Metastasis) AND (Exercise OR Physical Fitness OR Exertion OR Exercise Therapy OR Sports OR Exercise Movement Techniques OR Physical Fitness OR Physical Conditioning OR Physical Endurance) AND (Fracture Bone OR Fractures, Bone) AND (Exercise OR Physical Therapy) AND Fracture AND Neoplasm; (Bone Neoplasms OR Neoplasms Metastasis) AND (Exercise OR Physical Fitness OR Exertion OR Exercise Therapy OR Sports OR Exercise Movement Techniques OR Physical Fitness OR Physical Conditioning OR Physical Endurance) AND (Fracture Bone OR Fractures, Bone) AND (Exercise OR Physical Therapy) AND Fracture AND Neoplasm; (Neoplasms OR Carcinogens OR Tumor OR Cancer) AND (Signs and Symptoms Respiratory OR Dyspnea) AND (Breathing Exercise OR Exercise Therapy); (Neoplasms OR Carcinogens OR Tumor OR Cancer) AND (Oxygen Inhalation Therapy OR Positive Pressure Respiration OR PEEP); Neoplasms OR Cancer OR Tumor OR Carcinogens AND Terminally ill OR Terminal Care OR Palliative Care AND Oxygen Inhalation Therapy; Neoplasm AND (Muscle OR Muscle Strength OR Muscle Weakness OR Cachexia) AND (Androgens OR Anabolic Agents OR Nandrolone OR Oxandrolone) AND (Exercise OR Physical Therapy OR Rehabilitation); (Anthracyclines OR Trastuzumab OR Ciclofosfamide) AND (Physical Activity OR Exercise) AND (Cardiotoxicity); Neoplasm AND Thrombocytopenia AND (Exercise OR Rehabilitation OR Physical Therapy). Analisado esse material, selecionou-se os artigos relativos às perguntas e, por meio do estudo dos mesmos, originou-se as evidências que fundamentaram as diretrizes do presente documento.This study revised articles from the MEDLINE (PubMed) databases and other research sources, with no time limit. To do so, the search strategy adopted was based on (P.I.C.O.) structured questions (from the initials "Patient"; "Intervention"; "Control" and "Outcome". As keywords were used: (Neoplasms OR Carcinogens OR Tumors OR Cancer) AND (Fatigue OR Asthenia OR Lassitude OR Muscle Fatigue OR Fatigue OR Muscles OR specific muscle OR Mental Fatigue OR Fatigue, Mental OR Cancer-related fatigue) AND (Exercise OR Physical Fitness OR Exertion OR Exercise Therapy OR Sports OR Exercise Movement Techniques OR Physical Fitness OR Physical Conditioning OR Physical Endurance); (Neoplasms OR Carcinogens OR Tumors OR Cancer) AND (Fatigue OR Asthenia OR Lassitude OR Muscle Fatigue OR Fatigue OR Muscles OR Specific Muscle OR Mental Fatigue OR Fatigue, Mental OR Cancer-related Fatigue) AND (Chemotherapy, Adjuvant OR Combined Modality Therapy OR Drug Therapy,combination OR Antineoplastic Combined Chemotherapy Protocols) AND (Exercise Tolerance OR Oxigen Consumption*&nbsp;OR Exercise OR Physical Fitness OR Exertion OR Exercise Therapy OR Sports OR Physical Fitness OR Physical Conditioning OR Physical Endurance); (Neoplasms OR Carcinogens OR Tumors OR Cancer) AND (Fatigue OR Asthenia OR Lassitude OR Muscle Fatigue OR Fatigue OR Muscles OR specific muscle OR Mental Fatigue OR Fatigue, Mental OR cancer-related fatigue) AND (Exercise OR Physical Fitness OR Exertion OR Exercise Therapy OR Sports OR Exercise Movement Techniques OR Physical Fitness OR Physical Conditioning OR Physical Endurance OR Intensity exercise); (Neoplasms OR Carcinogens OR Tumors OR Cancer) AND (Fatigue OR Asthenia OR Lassitude OR Muscle Fatigue OR Cancer-related fatigue) AND (Exercise OR Physical Fitness OR Exertion OR Exercise Therapy OR Sports OR Sports OR Exercise Movement Techniques OR Physical Fitness OR Physical Conditioning OR Physical Endurance); Neoplasm AND (Exercise OR Physical Fitness OR Exertion OR Exercise Therapy OR Sports OR Exercise Movement Techniques OR Physical Fitness OR Physical Conditioning OR Physical Endurance) AND Quality of Life ; (Bone Neoplasms OR Neoplasms Metastasis) AND (Exercise OR Physical Fitness OR Exertion OR Exercise Therapy OR Sports OR Exercise Movement Techniques OR Physical Fitness OR Physical Conditioning OR Physical Endurance) AND (Fracture Bone OR Fractures, Bone) AND (Exercise OR Physical Therapy) AND Fracture AND Neoplasm; (Bone Neoplasms OR Neoplasms Metastasis) AND (Exercise OR Physical Fitness OR Exertion OR Exercise Therapy OR Sports OR Exercise Movement Techniques OR Physical Fitness OR Physical Conditioning OR Physical Endurance) AND (Fracture Bone OR Fractures, Bone) AND (Exercise OR Physical Therapy) AND Fracture AND Neoplasm; (Neoplasms OR Carcinogens OR Tumor OR Cancer) AND (Signs and Symptoms Respiratory OR Dyspnea) AND (Breathing Exercise OR Exercise Therapy); (Neoplasms OR Carcinogens OR Tumor OR Cancer) AND (Oxygen Inhalation Therapy OR Positive Pressure Respiration OR PEEP) ; Neoplasms OR Cancer OR Tumor OR Carcinogens AND Terminally ill OR Terminal Care OR Palliative Care AND Oxygen Inhalation Therapy; Neoplasm AND (Muscle OR Muscle Strength OR Muscle Weakness OR Cachexia) AND (Androgens OR Anabolic Agents OR Nandrolone OR Oxandrolone) AND (Exercise OR Physical Therapy OR Rehabilitation); (Anthracyclines OR Trastuzumab OR Ciclofosfamide) AND (Physical Activity OR Exercise) AND (Cardiotoxicity); Neoplasm AND Thrombocytopenia AND (Exercise OR Rehabilitation OR Physical Therapy). With the above keywords crossings were performed according to the proposed theme in each topic of the (P.I.C.O.) questions. After analyzing this material, articles regarding the questions were selected and, by studying those, the evidences that fundamented the directives of this document were established

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518

Purpose Treatment options for neuroendocrine tumors (NETs) remain limited. This trial assessed the progression-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-α-2b) added to octreotide among patients with advanced NETs. Patients and Methods Southwest Oncology Group (SWOG) S0518, a phase III study conducted in a US cooperative group system, enrolled patients with advanced grades 1 and 2 NETs with progressive disease or other poor prognostic features. Patients were randomly assigned to treatment with octreotide LAR 20 mg every 21 days with either bevacizumab 15 mg/kg every 21 days or 5 million units of IFN-α-2b three times per week. The primary end point was centrally assessed PFS. This trial is registered with ClinicalTrials.gov as NCT00569127. Results A total of 427 patients was enrolled, of whom 214 were allocated to bevacizumab and 213 to IFN-α-2b. The median PFS by central review was 16.6 months (95% CI, 12.9 to 19.6 months) in the bevacizumab arm and was 15.4 months (95% CI, 9.6 to 18.6 months) in the IFN arm (hazard ratio [HR], 0.93; 95% CI, 0.73 to 1.18; P = .55). By site review, the median PFS times were 15.4 months (95% CI, 12.6 to 17.2 months) for bevacizumab and 10.6 months (95% CI, 8.5 to 14.4 months) for interferon (HR, 0.90; 95% CI, 0.72 to 1.12; P = .33). Time to treatment failure was longer with bevacizumab than with IFN (HR, 0.72; 95% CI, 0.58 to 0.89; P = .003). Confirmed radiologic response rates were 12% (95% CI, 8% to 18%) for bevacizumab and 4% (95% CI, 2% to 8%) for IFN. Common adverse events with bevacizumab and octreotide included hypertension (32%), proteinuria (9%), and fatigue (7%); with IFN and octreotide, they included fatigue (27%), neutropenia (12%), and nausea (6%). Conclusion No significant differences in PFS were observed between the bevacizumab and IFN arms, which suggests that these agents have similar antitumor activity among patients with advanced NETs